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Background: Methods for the cost-effectiveness analysis of health technologies are now well established, but such
methods may also have a useful role in the context of evaluating the effects of variation in applied clinical practice.
This study illustrates a general methodology for the comparative analysis of applied clinical practice at alternative
institutions – risk adjusted cost-effectiveness (RAC-E) analysis – with an application that compares acute hospital
services for stroke patients admitted to the main public hospitals in South Australia.
Methods: Using linked, routinely collected data on all South Australian hospital separations from July 2001 to June
2008, an analysis of the RAC-E of services provided at four metropolitan hospitals was undertaken using a decision
analytic framework. Observed (plus extrapolated) and expected lifetime costs and survival were compared across
patient populations, from which the relative cost-effectiveness of services provided at the different hospitals
was estimated.
Results: Unadjusted results showed that at one hospital patients incurred fewer costs and gained more life years
than at the other hospitals (i.e. it was the dominant hospital). After risk adjustment, the cost minimizing hospital
incurred the lowest costs, but with fewer life-years gained than one other hospital. The mean incremental cost per
life-year gained of services provided at the most effective hospital was under $20,000, with an associated 65%
probability of being cost-effective at a $50,000 per life year monetary threshold.
Conclusions: RAC-E analyses can be used to identify important variation in the costs and outcomes associated
with clinical practice at alternative institutions. Such data provides an impetus for further investigation to identify
specific areas of variation, which may then inform the dissemination of best practice service delivery
and organisation.Background
Evidence-based clinical guidelines have been developed
for the treatment of acute stroke events, which define re-
commended processes for diagnosing, treating, and moni-
toring stroke [1]. However, clinical practitioners are well
aware that the dissemination of guidelines does not pre-
vent the emergence of differences in practices between
clinical services. The dilemma is how to evaluate the out-
come of the day-to-day practices of different services in
such a way as to identify the areas of variations that have
long-term benefits for patient care. This is particularly* Correspondence: clarabelle.pham@adelaide.edu.au
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reproduction in any medium, provided the orimportant when reducing variation requires resources
over and above currently allocated budgets, but the bene-
fits to patients accrue over time, without being identifiable
at the point of discharge from hospital. Evaluating service
differences as investments rather than costs is a constant
source of friction between health practitioners and the
funders of health services.
Cost-effectiveness analysis is now well established in
relation to pharmaceuticals and medical technology, but
not in relation to broader institutional level variations in
day-to-day clinical practice. This precludes the identi-
fication of efficient practice, and the establishment of
processes to guide and finance investment in service de-
livery and organisation (as are established in many coun-
tries for specific health care technologies). The gap intd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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to the complex nature of evaluating alternative forms of
routine clinical practice.
Linked routinely collected data provides a potentially
useful data source for the evaluation of clinical practice,
with the benefits of rapid and inexpensive access to large
amounts of data that describes real world activity. In-
ternationally, systems are currently being developed to
increase availability and access to linked routinely col-
lected data. We have developed a novel methodology
that uses linked routinely collected data to evaluate the
long-term costs and benefits of services for specific con-
ditions provided at alternative hospitals (risk adjusted
cost-effectiveness (RAC-E) analysis) [2,3]. This paper re-
ports an application of the RAC-E methodology to evalu-
ate the relative cost-effectiveness of acute stroke services
at the four main public hospitals in South Australia (SA).Methods
Figure 1 illustrates the RAC-E analytic framework. In
the first stage, all eligible patients with an initial stroke
event over an extended time horizon (from July 2002 to
June 2008) are assigned to one of four mutually exclu-
sive intermediate endpoints representing the first (if any)
event of interest. Separate datasets for the ‘no relatedHospital 1 
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Figure 1 RAC-E analytic framework.readmission nor death’, ‘non-fatal recurrent stroke’ and
‘non-fatal cardiac event’ cohorts are created.
Using the three datasets, separate estimates of overall
survival from the time of their intermediate endpoint
are estimated for each patient by fitting parametric
survival curves to the observed data. Long-term costs
are generated alongside the parametric survival models,
using multivariate regression models to predict annual
cost estimates.
The ‘observed + extrapolated’ cost and survival esti-
mates for the cohort of interest (patients with a new
stroke between July 2005 and June 2006) across the four
intermediate endpoints are then combined into a single
dataset. This dataset is analyzed using multivariate re-
gression models to generate estimates of expected costs
and survival for each patient, from the time of their ini-
tial stroke separation.
Combining the above data for all patients with a stroke
separation between July 2005 and June 2006, risk ad-
justed cost and survival estimates are generated as the
‘observed + extrapolated’ values minus the correspon-
ding expected values for each patient. Mean risk ad-
justed cost and survival estimates are then generated
for each hospital, which inform estimates of incremental
cost-effectiveness between the clinical processes at the al-
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Routinely collected data was obtained and linked from
the following sources:
 Hospital separation data
4,072,341 records from the Integrated South
Australian Activity Collection (ISAAC), describing
patient, admission, and inpatient stay characteristics
for all hospital separations in South Australia from
July 2001 to June 2008. Co-morbidity variables were
coded based on the current clinical performance
indicators for the Variable Life Adjusted Display
(VLAD) system using ICD-10.5-AM codes [4].
 Socioeconomic data
Area (postcode) level variables describing
socioeconomic areas, socioeconomic disadvantage,
economic resources, and education and occupation.
 Costing data
1,530,634 separation-specific cost estimates at the
four largest hospitals in South Australia from July
2003 to June 2008, presented in 16 categories
covering direct and indirect ward, surgery, allied
health, diagnostics, pharmacy, and prostheses
related costs.
 All-cause mortality data
92,288 deaths from the Register for Births,
Deaths, and Marriages between July 2001 and
December 2008.
The separations within the ISAAC data were linked
deterministically using an algorithm that specified
thresholds for positive linkages over a set of common
identifiers [5,6]. The costing and socioeconomic data
were matched with the ISAAC data on the basis of
hospital-specific identification numbers and postcodes,
respectively. The mortality and ISAAC data were linked
probabilistically using mathematical algorithms to deter-
mine the likelihood that a pair of records refers to the
same individual given a set of common identifiers. Ex-
tensive clerical review was also undertaken to confirm
the linkages between the mortality and ISAAC data.
Ethics approval was granted by the South Australian
Department of Health Human Research Ethics Committee
(HREC Protocol No.: 264/11/2011).
Study cohort
Stroke separations may be identified via ICD-10.5-AM
principal diagnosis codes and AR-DRG codes. Inclusion
criteria for the study included ICD principal diagnosis
codes for stroke (I60-I64) and an AR-DRG stroke code
(B70), which includes sub-categories that differentiate
according to the presence of catastrophic (B70A), se-
vere (B70B), and neither catastrophic or severe (B70C)
comorbidities or complications. Other AR-DRG codeswith a principal diagnosis of stroke included craniotomy
(B02), extracranial vascular procedure (B04) and tracheos-
tomy or ventilation >95 hours (A06), which were exclu-
ded in order to increase the homogeneity of the defined
patient cohort. Other exclusion criteria included deaths
within 5 days of admission, which was assumed to be out-
side the influence of acute hospital care.
The main study cohort comprised patients admitted to
one of the four study hospitals with a B70 AR-DRG code
in the year to June 30, 2006, excluding patients with a
documented stroke diagnosis in the year prior to this
date. Using the Brameld-Holman backcasting method
[7] to address the prevalent pool effect, it was deter-
mined that this cut-off date provided a 90% probability
that the first observed stroke was a new stroke.Extrapolation analysis
To inform the extrapolated analysis of lifetime costs
and survival, all patients with a new stroke admission
(as defined for the study cohort) from July 1, 2002 were
allocated to one of the four intermediate endpoints:
non-fatal recurrent stroke; non-fatal major cardiac event;
death without, or within 28 days of a non-fatal stroke or
major cardiac event; or no subsequent event. These data
provided follow-up data of up to 6 years to inform the
extrapolation analyses, i.e. follow-up data on all patients
experiencing an intermediate event were available to
June 2008, unless they died in the interim period.
Non-fatal recurrent stroke was defined as any hospital
admission with an ICD principal diagnosis of stroke.
Based on an analysis of survival of stroke patients fol-
lowing any readmission within Major Disease Category 5
(Diseases of the Circulatory System), twenty DRG codes
with a mean 1-year mortality rate of 40% or greater
were defined as non-fatal major cardiac events. Both
non-fatal events excluded patients who died within 28 days
of admission, and hospital transfers from the index
stroke admission.
The following sections describe the methods used to
extrapolate lifetime costs and survival beyond each inter-
mediate endpoint.Survival models
Flexible parametric models for survival analysis, intro-
duced by Royston and Parmar [8], were applied to the
three intermediate endpoint datasets (containing patients
experiencing a non-fatal stroke, non-fatal cardiac event, or
no subsequent event, respectively) to predict survival be-
yond each intermediate endpoint. Every patient in the
datasets had a recorded date of death, or they were cen-
sored at the end of the follow-up period (30 June 2008).
Explanatory variables were based on patient clinical and
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termediate event (as described in the data section).
The applied survival models used restricted cubic
splines to estimate log cumulative hazards, controlling
for the effect of relevant patient characteristics. This is a
general approach for adapting linear methods to model
non-linear relationships through the use of multiple points
of inflexion (knots) across the modeled time horizon [9].
To fit the models, we used backwards stepwise selec-
tion using the full range of demographic, socioeconomic,
and clinical explanatory variables. The criterion for in-
clusion in the model was p ≤ 0.05. These initially defined
models were then expanded to test for significant inter-
actions between the included explanatory variables.
Interaction terms were included in the models if they
improved model fit, as judged by the Akaike's Informa-
tion Criterion. The final stage of the analysis tested the
effect of alternative functional forms by comparing mo-
dels that fitted a restricted cubic spline with between 1
and 5 knots. To assess the overall fit of the parametric
survival models, the mean survival curve was plotted
against the Kaplan-Meier survival curve.
The resulting survival functions were used to estimate
annual age-specific probabilities of survival, conditional
on surviving to each starting age. For each patient, these
probabilities were used to estimate a mean survival time
between patients’ age at the time of their intermediate
endpoint event and age 100 years. A 5% discount rate
was applied to the survival estimates, in accordance with
the Pharmaceutical Benefits Advisory Committee guide-
lines [10].
Cost models
The cost data within the three intermediate endpoint
datasets were formatted to estimate annual cost variables
for each full year of life between patients’ intermediate
endpoint and their recorded date of death or the end of
the follow-up period (30 June 2008). Costs associated
with any stroke or cardiac related hospital admissions
were included.
Using the same explanatory variables as used in the
survival models, annual costs were estimated using a
two-stage process that estimated the probability of pa-
tients incurring any costs (using logistic regression), fol-
lowed by an estimate of the magnitude of the cost, if
incurred (using generalized linear models - GLMs). Se-
parate models were fitted for each of the three inter-
mediate endpoint datasets, with additional models that
differentiated between costs incurred in the first year
post-event and in subsequent years for the non-fatal
stroke and non-fatal cardiac event endpoints [11].
Similar model selection criteria to those used for the
survival models were applied. For the logistic regression
analyses, overall model fit was established using theRamsey RESET test. For each GLM, the modified Park
test was used to determine the most appropriate distri-
bution, and the appropriate link function was selected
by testing different power functions with respect to the
Pearson correlation, Pregibon link, and the Modified
Hosmer-Lemeshow tests.
For each patient, the predicted annual cost estimates
were combined with the annual survival probabilities
generated from the survival models to estimate mean
lifetime costs, i.e. the product of the discounted annual
survival probabilities and corresponding annual cost
estimates were summed across the time period between
their intermediate endpoint event and age 100 years.
Observed lifetime costs and survival
From the index stroke event, lifetime cost and survival
estimates for each patient were generated, given their ex-
perienced intermediate endpoint (non-fatal stroke; non-
fatal major cardiac event; no subsequent event; or death).
These estimates combined observed costs and survival
during the period between the index stroke event and
each patient’s intermediate endpoint, with extrapolated
costs and survival time beyond the intermediate endpoint
(other than for patients who died during the follow-
up period, for whom only observed costs and survival
were used).
Despite incorporating predicted values, these cost and
survival estimates are labeled as ‘observed’ values be-
cause they reflect the effects of the observed interme-
diate endpoints.
Expected lifetime costs and survival
The observed lifetime costs and survival estimates for all
eligible patients (i.e. across all four intermediate end-
points, for patients with a new stroke in the year to June
30, 2006) were combined into a single dataset. A GLM
and a flexible parametric survival model [8] were then
fitted to generate patient-specific estimates of expected
lifetime costs and survival, respectively. Explanatory cli-
nical and socio-demographic variables for these models
reflected patient characteristics at the time of the in-
dex event (i.e. not controlling for the observed inter-
mediate events).
Main data analysis
Mean estimates of observed costs and survival across all
patients treated at each hospital were derived, informing
unadjusted estimates of the cost-effectiveness of services
provided at the alternative hospitals.
Risk adjusted cost and survival estimates for each pa-
tient were generated as the relevant observed minus
expected values, which provide a more intuitive inter-
pretation of hospital performance than ‘observed divided
by expected’ adjusted values.
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cost and survival estimates between hospitals can be in-
terpreted as risk adjusted differences in costs and sur-
vival: if costs incurred by patients at hospital A are $300
more than expected, whilst costs incurred by patients at
hospital B are $200 less than expected, then the risk
adjusted difference in per patient costs between hospitals
A and B is $500. Revised incremental cost-effectiveness
ratios were generated using these risk adjusted values.
A probabilistic sensitivity analysis was informed by a
multi-stage bootstrapping (sampling with replacement)
process, which precluded the need to parameterize the
correlation between lifetime costs and survival. Firstly,
the datasets informing each of the extrapolation regres-
sion models (10 cost models and 3 survival models) were
bootstrapped, and the corresponding model coefficients
re-estimated to generate new estimates of lifetime costs
and survival for each eligible patient. The resulting data-
set of ‘observed’ lifetime costs and survival was also
bootstrapped and the coefficients for the expected costs
and survival regression models re-estimated. This se-
quential bootstrapping process was repeated for 2,000
iterations, and the resulting outputs were used to plot
cost-effectiveness acceptability curves that display the
probability that each hospital is cost-effective at different
threshold values for gaining additional life years.Table 1 Stroke patient characteristics by hospital
Hospital A Hos
Age (mean (SD), years) 75.9 (11.4) 76.2
Sex (% male) 51
Stroke severity (%):
B70A (Stroke + CCC) 29
B70B (Stroke + SCC) 38
B70C (Stroke -CSCC) 33
Intermediate outcome (% patients):
No event 64
Recurrent stroke 6
Major cardiac event 7
Death within 2 years 23
Co-morbidities (% patients):
Other COPD 7
Anaemia 8
Diabetes mellitus 24
Acute LRTI & influenza 10
UTI 11
Other urinary symptoms 16
Minor vascular comorbidity 78
Socioeconomic disadvantage* 17
* Percentage of patients in the lowest quintile of socioeconomic disadvantage.
NS indicates not significant (p > 0.10); COPD, chronic obstructive pulmonary diseaseAll analyses were undertaken using Stata, release 11.0
(StataCorp LP).Results
Key patient characteristics for the eligible cohort of
stroke patients presenting in the year to June 30 2006
are presented in Table 1. The only significant variation
in patient casemix concerned socioeconomic disadvan-
tage (p < 0.001), with patients at hospital D classified as
the most disadvantaged.
Details of the multivariate regression models that ex-
trapolated cost and survival to a lifetime horizon, as well
as to estimate expected lifetime costs and survival, are
presented in Additional file 1: Tables S1, S2, S3. The
models include alternative sets of clinical and socio-
demographic explanatory variables, indicating an effect
of socioeconomic status that is additional to associations
with poor health status. The survival curve plots indicate
that the survival models were of good fit and produced
sensible estimates (see Additional file 2: Figure S1 for
the mean survival curve versus Kaplan-Meier survival
curve plots for each intermediate endpoint). Table 2 pre-
sents observed, expected, and risk adjusted lifetime costs
and survival (life-years), as well as the associated incre-
mental costs per life year gained.pital B Hospital C Hospital D P-value
(10.4) 73.3 (12.6) 72.0 (14.3) 0.003
46 54 51 NS
0.001
46 31 30
34 35 43
20 34 27
0.063
57 54 53
5 5 9
6 13 9
32 28 29
12 6 12 0.045
15 10 12 NS
31 19 22 0.036
11 10 8 NS
28 22 15 <0.001
12 13 12 NS
81 66 84 <0.001
51 21 73 <0.001
; LRTI, lower respiratory tract infection; UTI, urinary tract infection.
Table 2 Unadjusted and adjusted lifetime costs, survival, and incremental cost-effectiveness
Hospital Observed* Incremental cost per
LY gained
Expected Standardized† Incremental cost
per LY gainedMean costs Mean survival Mean costs Mean survival Mean costs Mean survival
B $ 16,504 6.202 Dominated by hospitals
A, C & D
$ 16,056 6.442 $ 449 −0.24 Dominated by
hospitals A & D
C $ 16,073 7.903 Dominated by hospital D $ 15,244 8.084 $ 829 −0.18 Dominated by
hospitals A & D
D $ 12,471 8.139 Dominant $ 16,855 8.088 -$ 4,384 0.05 -
A $ 15,157 7.463 Dominated by hospital D $ 14,626 7.098 $ 532 0.37 $ 15,632 (D vs. A)
Costs are reported in AUD. LY indicates life years.
*In line with the text, observed costs and survival incorporate predicted values beyond the observed intermediate endpoints, they are labeled as ‘observed’ values
because they reflect the effects of the observed intermediate endpoints.
†Standardized costs and survival are estimated as observed minus expected values.
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lowest mean costs and the highest mean survival, and
therefore dominated the other hospitals.
The risk adjusted analysis shows that for both hospi-
tals B and C, at least one other hospital had lower costs0
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Figure 2 Cost-effectiveness acceptability curves for A) all 4 included hand higher survival (i.e. they were dominated). However,
after risk adjustment, mean survival is greater for hos-
pital A than for hospital D, though D remains the least
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the discount rates from 5% to 2% and 0% decreased the
incremental cost per life year gained to $12,016 and
$10,720, respectively.
The results of the probabilistic sensitivity analysis are
presented in the form of cost-effectiveness acceptability
curves in Figure 2a, which shows the probability that
each of the hospitals is the most cost-effective hospital
at different monetary values for gaining life years. Hospital
A has a 65% probability of being the most cost-effective
hospital at a life year value of $50,000 – a commonly im-
plied threshold. Comparing hospitals A and D directly
(Figure 2b), hospital A had a 70% probability of being the
most cost-effective hospital at a threshold of $ 50,000.
Descriptive analyses
The RAC-E results provide an indication of the conse-
quences of variation in clinical practice. The next stageTable 3 Characteristics of stroke patients who did and did no
Hospital A Hospital
B70A (STROKE + CCC)
Rehabilitation:
Age (mean (sd), years) 79.6 (10.0) 76.4 (9.4)
Proportion with rehab (%) 35 24
Acute LoS (mean (sd), days) 18.3 (11.2) 23.9 (14.6
Rehab LoS (mean (sd), days) 23.6 (12.7) 39.4 (27.3
No rehabilitation:
Age (mean (sd), years) 83.7 (7.0) 79.7 (8.5)
Acute LoS (mean (sd), days) 20.8 (15.0) 21.2 (12.1
B70B (STROKE + SCC)
Rehabilitation:
Age (mean (sd), years) 71.7 (10.5) 75.8 (11.5
Proportion with rehab (%) 45 47
Acute LoS (mean (sd), days) 12.5 (7.8) 11.8 (8.2)
Rehab LoS (mean (sd), days) 23.9 (17.6) 34.4 (21.5
No rehabilitation:
Age (mean (sd), years) 76.3 (12.0) 73.8 (10.4
Acute LoS (mean (sd), days) 13.4 (11.5) 13.3 (10.1
B70C (STROKE -CSCC)
Rehabilitation:
Age (mean (sd), years) 72.1 (10.8) 71.0 (6.6)
Proportion with rehab (%) 22 20
Acute LoS (mean (sd), days) 9.9 (5.1) 8.0 (5.7)
Rehab LoS (mean (sd), days) 23.9 (24.0) 38.4 (24.9
No rehabilitation:
Age (mean (sd), years) 72.3 (11.5) 72.3 (12.2
Acute LoS (mean (sd), days) 5.8 (8.0) 8.5 (15.8)
+CCC – catastrophic complication or comorbidity; +SCC - severe complication or como
NS indicates not significant (p > 0.10); LoS, length of stay.is to investigate areas of variation and potential causes of
the estimated differences in RAC-E. The following para-
graphs describe some preliminary analyses of the available
process data relating to the eligible patient cohort.
Table 3 presents available data on length of stay, and
the use of rehabilitation services. The observed lower
costs at hospital D may be mainly explained by the
reduced LoS across all levels of stroke severity, though
particularly for patients with catastrophic CC, for whom
mean LoS is at least 10 days shorter at hospital D than
at any other hospital. More patients at hospital D re-
ceived sub-acute rehabilitation in each of the stroke
categories, though the inter hospital differences were not
statistically significant. With respect to LoS for sub-
acute rehabilitation, it is noticeable that patients going
onto rehabilitation from Hospitals B and C had signifi-
cantly longer lengths of stay than patients at Hospitals A
and D.t have rehabilitation by stroke severity
B Hospital C Hospital D P-value
74.4 (10.7) 76.2 (13.7) NS
32 44 NS
) 18.3 (13.2) 8.1 (3.5) <0.001
) 42.0 (38.2) 24.4 (10.2) <0.001
79.2 (9.4) 79.3 (12.6) 0.017
) 22.9 (20.7) 9.7 (6.8) <0.001
) 72.4 (11.3) 68.8 (12.2) NS
45 54 NS
12.8 (5.8) 7.9 (4.2) 0.003
) 41.6 (27.8) 25.4 (9.5) <0.001
) 72.4 (14.8) 75.9 (12.1) NS
) 10.1 (9.2) 8.3 (6.3) 0.028
70.3 (10.5) 66.6 (13.3) NS
23 41 NS
9.5 (6.5) 8.7 (7.7) NS
) 22.7 (16.6) 25.2 (12.3) NS
) 70.0 (13.7) 64.5 (17.7) NS
6.0 (5.8) 3.8 (2.6) <0.001
rbidity; -CSCC - neither catastrophic nor severe complication or comorbidity.
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costing data. The cost differences correlate with the ob-
served differences in LoS, with hospital D having the
lowest costs in each category. Comparing the most cost-
effective hospital A, with the dominated hospitals B and
C, hospital A has consistently higher allied health costs,
and lower imaging, pathology, and pharmacy costs. This
may be indicative of alternative foci with respect to the
management of acute stroke patients.
Discussion
The results from this study indicate variation in risk
adjusted lifetime costs and outcomes associated with
acute stroke services at the four largest metropolitan
hospitals in South Australia. The mean results imply that
if patients currently treated at hospital D were to be
treated at hospital A, we could gain life years at a cost of
$15,632 per additional life year. If this is considered to
be a cost-effective use of resources, the care pathways
should be investigated with a view to disseminating prac-
tice at hospital A to the other hospitals.Table 4 Breakdown of Stroke costs by DRG for each hospital
COST CATEGORIES* Mean (SD) Costs
Hospital A Hospital B
B70A (STROKE + CCC)
Medical Ward 817 (556) 1,436 (912)
Nursing Ward 5,222 (4,595) 6,480 (4,994)
Allied Health 1,406 (1,100) 799 (439)
Imaging 437 (254) 483 (331)
Pathology 251 (164) 534 (473)
Pharmacy 381 (362) 489 (315)
ICU 63 (405) 145 (777)
B70B (STROKE + SCC)
Medical Ward 503 (355) 925 (736)
Nursing Ward 2,461 (2,862) 3,356 (3,406)
Allied Health 994 (787) 532 (421)
Imaging 380 (238) 419 (304)
Pathology 179 (235) 276 (241)
Pharmacy 239 (254) 340 (283)
ICU 440 (2,796) 152 (857)
B70C (STROKE -CSCC)
Medical Ward 337 (317) 476 (699)
Nursing Ward 1,092 (1,134) 1,355 (2,255)
Allied Health 504 (636) 240 (227)
Imaging 318 (251) 376 (341)
Pathology 103 (65) 174 (184)
Pharmacy 140 (166) 207 (289)
ICU 30 (240) 0 (0)
*Direct costs are provided only, does not include overhead costs. ICU indicates inteThe risk adjustment process was important as the un-
adjusted analysis showed hospital D to dominate all
three other hospitals (i.e. to cost less and gain more),
mainly due to the younger age of the patient cohort
attending that hospital. Hospital D also had a catchment
area that includes lower socioeconomic areas than the
other hospitals, which was captured as an area level va-
riable in the risk adjustment process. The use of area
level socioeconomic data generally reduces the differ-
ences between the groups at the ends of the advantaged-
disadvantaged spectrum [12], but as we are comparing
mean values across multiple areas, the aggregated nature
of the socioeconomic data is unlikely to have a signifi-
cant effect on the RAC-E analysis. This is convenient as
individual level socioeconomic variables are difficult to
specify via routinely collected data sources.
We propose that RAC-E analyses be undertaken to
identify areas of clinical practice in which there are im-
portant differences in costs and outcomes at alternative
institutions. Where important differences are identified,
a second stage comparative analysis of process may beHospital C Hospital D P-value
1,335 (1,085) 747 (532) <0.001
4,964 (4,628) 2,376 (2,243) <0.001
951 (811) 362 (312) <0.001
556 (480) 277 (273) <0.001
627 (512) 180 (228) <0.001
389 (567) 208 (145) 0.006
492 (2,215) 100 (623) NS
715 (638) 693 (487) <0.001
2,365 (2,848) 1,588 (1,213) 0.006
555 (458) 238 (202) <0.001
381 (340) 240 (237) 0.005
295 (192) 128 (114) <0.001
180 (290) 183 (115) <0.001
100 (516) 30 (220) NS
396 (338) 462 (404) NS
1,010 (1,301) 908 (894) NS
235 (284) 114 (181) <0.001
407 (421) 229 (286) 0.039
223 (156) 97 (137) <0.001
168 (430) 116 (94) NS
40 (223) 37 (145) NS
nsive care unit.
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ical practice processes that may be contributing to the
estimated differences in costs and outcomes.
This paper has identified important differences in costs
and outcomes across the four hospitals, but only prelimi-
nary data relating to the applied clinical practice processes
are currently available. Interestingly, of the three hospitals,
only hospital D did not have a specialized stroke unit. The
other main difference was between the services provided
at Hospitals A, B, and C, which indicated greater use of al-
lied health at the more effective Hospital A, with larger
imaging, pathology, and pharmacy costs at the less effec-
tive Hospitals B and C.
More detailed data are available from routine data sys-
tems other than those accessed to inform the presented
RAC-E analysis. These data will inform more detailed
analyses of clinical practice in the future, including as-
pects such as the use of specific technologies, such as
tissue plasminogen activator (tPA) and magnetic reso-
nance imaging (MRI), as well as data describing the timing
of key events along the process, such as time to tPA, or
time to inpatient admission.
A previous observational cohort study, comparing costs
and survival of stroke patients across Europe, also noted
that spending more on stroke services did not necessarily
improve outcomes [13], which is the case here for Hospi-
tals B and C. Grieve et al. [13] also identified differences
in process, finding that the type of staff input varied across
centres: nursing input at a stroke unit in Florence was
provided entirely by fully qualified nurses, whereas at a
stroke unit in London, 40% of the nurses had only
received a basic level of training.
Limitations
The use of routinely collected data provides access to a
large and representative sample of eligible patients, but
is reliant on data recorded for purposes other than re-
search. Perhaps the most significant limitation concerned
the use of AR-DRG and ICD-10 diagnostic codes to repre-
sent stroke severity and presence of co-morbidities, which
provides limited scope to differentiate between patients.
The inclusion of socioeconomic variables may reflect
some of the unobservable variation in casemix [14],
but future RAC-E applications will investigate the use
of alternative data sources that facilitate greater differ-
entiation between patients, for example, defining the
extent to which a diabetic co-morbidity is controlled by
accessing pathology reports.
The quality of the diagnosis-related variables is sub-
ject to the accuracy with which relevant information is
recorded in patient notes, and then extracted by data
coders. However, the coded data informs a significant
proportion of each hospital’s budget, providing common
incentives to all hospitals. Central audits also provideassurance of coding quality, and more importantly the
lack of systematic differences between the hospitals.
There are also uncertainties around the data linkage,
though again there is no reason to suspect systematic
bias in the linkage processes. Going forward, current in-
vestments in data linkage facilities across Australia will
improve linkage processes, providing access to a broader
range of health care data (e.g. covering primary and se-
condary settings), as well as placing a greater emphasis
on improving data quality and recording practices.
The analysis included only data describing inpatient
hospital admissions, linked to population-based mortality
data. The exclusion of other hospital or community-based
services will not affect the measurement of outcomes, but
could misrepresent cost differences. We emphasize that
the purpose of the reported analyses is not to make defi-
nite conclusions regarding the relative cost-effectiveness
of services provided at different hospitals, but to inform
further investigation of the underlying causes of the es-
timated differences in cost-effectiveness. Further investi-
gations might assess differences in clinical pathways using
improvement tools such as process mapping [15,16], or
process mining [17], to describe patient journeys and gain
a better understanding of the content, sequence, and ti-
ming of the health care provided at different hospitals, in-
cluding activities such as post-discharge monitoring and
referrals to community-based health programs.Conclusion
Despite the development of evidence-based clinical prac-
tice guidelines for the management of acute stroke, the
uptake of guidelines has been variable. Translating evi-
dence into practice is challenging, as it often requires
investment at both the organisational and practitioner
levels [18]. The presented RAC-E methodology quanti-
fies the costs and effects of variation in alternative cli-
nical practice processes. Combined with complementary
process analyses that identify specific areas of variation
in clinical practice, RAC-E analyses are hypothesized to
provide a powerful tool to aid the dissemination and up-
take of best clinical practice.Additional files
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